Addendum
Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08
Report documents
-
Addendum
Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08
Dossier assessment
Indication:
Cystic fibrosis (CF) in 6 to 11 year old children who are homozygous for the F508del mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A18-08 unchanged
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-39
- Commission
- Commission awarded on 13.06.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed